---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011834"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:26:19.362318+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics Reports FY2023 Revenue Decline, 27% OpEx Reduction, and FDA Clearance for Severe OSA

## Summary
- Revenue for Q4 2023 was $3.2M and full year $13.8M, down from $4.0M and $16.0M in 2022, due to lower appliance revenue and VIP enrollments.
- Operating expenses decreased 27% in FY2023, leading to a 43% reduction in net loss, as cost-cutting initiatives took effect.
- In November 2023, Vivos received FDA 510(k) clearance for its CARE oral appliances to treat severe OSA in adults, a first for oral devices.
- Signed VIP enrollment contracts increased 38% sequentially in Q4 2023 following the FDA clearance, indicating improved business momentum.
- Cash and equivalents were $1.6M at year-end; a warrant exercise in February 2024 generated $4.0M in gross proceeds.

## SEC filing metadata
- accession: 0001493152-24-011834
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315224011834/0001493152-24-011834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315224011834/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011834
- JSON: https://secwatch.observer/filing/0001493152-24-011834.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011834.txt

## Key facts
- Earnings Releases
  Vivos Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On March 28, 2024, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315224011834/0001493152-24-011834-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.